Provided by Tiger Trade Technology Pte. Ltd.

Cogent

9.09
-0.2400-2.57%
Post-market: 9.05-0.0400-0.44%19:30 EDT
Volume:2.17M
Turnover:19.39M
Market Cap:465.55M
PE:-9.65
High:9.37
Open:9.20
Low:8.60
Close:9.33
52wk High:45.69
52wk Low:8.60
Shares:51.22M
Float Shares:45.32M
Volume Ratio:1.01
T/O Rate:4.79%
Dividend:0.08
Dividend Rate:0.88%
EPS(TTM):-0.9421
EPS(LYR):-3.8009
ROE:-721.50%
ROA:-1.24%
PB:-13.64
PE(LYR):-2.39

Loading ...

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

GlobeNewswire
·
Jun 12

Cogent Biosciences Shareholders Back Board, Governance Proposals

TIPRANKS
·
Jun 12

A Look At Cogent Communications Holdings (CCOI) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Jun 01

Cogent Biosciences announces data from analysis of PEAK Phase 3 trial

TIPRANKS
·
Jun 01

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
May 30

Cogent Communications Shares Fall After JPMorgan Downgrade

MT Newswires Live
·
May 30

Cogent Biosciences Price Target Maintained With a $55.00/Share by Wedbush

Dow Jones
·
May 29

Cogent Communications Cut to Neutral From Overweight by JP Morgan

Dow Jones
·
May 29

JPMorgan Downgrades Cogent Communications to Neutral From Overweight, $22 Price Target

MT Newswires Live
·
May 29

U.S. RESEARCH ROUNDUP-Autodesk, Dell Technologies, Hyatt Hotels

Reuters
·
May 29

Cogent Communications Holdings Inc : JP Morgan Cuts to Neutral From Overweight

THOMSON REUTERS
·
May 29

Cogent downgraded to Neutral from Overweight at JPMorgan

TIPRANKS
·
May 29

Cogent Communications director Lewis Ferguson disposes of 2,800 common shares worth $57,008

Reuters
·
May 29

Cogent Biosciences announces FDA acceptance of bezuclastinib NDA

TIPRANKS
·
May 28

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

GlobeNewswire
·
May 28

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
May 27

Cogent Comms Sells U.S. Data Centers to Investor

TIPRANKS
·
May 27

ADVISORY-Alert incorrectly tagged to Palo Alto Networks and Cogent Communications withdrawn

Reuters
·
May 27

Jvp Marks Strong Q1 2026 With Four Strategic Exits

THOMSON REUTERS
·
May 27

I Squared Capital Agrees to Buy Data Centers as Part of $1 Billion Platform Push

Dow Jones
·
May 26